, Tracking Stock Market Picks
Enter Symbol:
Aeterna Zentaris, Inc. (AEZS) [hlAlert]

down 99.35 %

Aeterna Zentaris, Inc. (AEZS) rated Buy

Posted on: Wednesday,  Aug 15, 2007  9:25 AM ET by RBC Capital Mkts

RBC Capital Mkts rated Buy Aeterna Zentaris, Inc. (NASDAQ: AEZS) on 08/15/2007, when the stock price was $14.04.
Since then, Aeterna Zentaris, Inc. has lost 99.36% as of 12/02/2015's recent price of $0.09.
If you would have followed this RBC Capital Mkts's recommendation on AEZS, you would have lost 99.35% of your investment in 3031 days.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology. The product pipeline of the Company encompasses compounds at all stages of development, from drug discovery through marketed products. The Company’s principal product candidates include cetrorelix for benign prostatic hyperplasia (BPH) and AEZS-108 for endometrial and ovarian cancers. In January 2007, the Company completed the spin-off of Atrium Biotechnologies Inc., known as Atrium Innovations (Atrium). On November 30, 2007, the Company completed the sale of its Utah-based subsidiary, Echelon Biosciences Inc. (Echelon), to Frontier Scientific Inc.

RBC Capital Markets is an international corporate and investment bank that provides innovative solutions and a focused set of products and services to institutions, corporations, governments and high net worth clients around the world. With nearly 3,700 professional and support staff, we operate out of 75 offices in 15 countries and deliver our products and services through operations in Asia and Australasia, the UK and Europe and in every major North American city.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/15/2007 9:25 AM Buy
as of 8/27/2015
1 Week down  -47.05 %
1 Month down  -67.85 %
3 Months down  -79.54 %
1 YTD down  -93.47 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy